Cocaine Vaccination works in 38% of subjects

Researchers at Bayer College of Medicine in Houston Texas have concluded the first part of Cocaine vaccination trials, and found the vaccine clinically effects 38% of subjects.

The vaccine uses the immune system to block the effects of cocaine and may be used in treating cocaine addiction – provided larger studies support the provisional idicators of effect and clinical safety.

It is not likely to be a treatment option for at least 3-5 years